Novabay Pharmaceuticals Incの価格/販売
Novabay Pharmaceuticals Incの価格/販売は何ですか。
Novabay Pharmaceuticals Incの価格/販売は0.27です。
価格/販売の定義は何ですか。
価格対売上比率は、収益と比較した会社の株価です。
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
NYSEMKTのセクタHealth Careにおける価格/販売の企業と比べるNovabay Pharmaceuticals Inc
Novabay Pharmaceuticals Incは何をしますか。
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Novabay Pharmaceuticals Incと類似の価格/販売
- Walgreens Boots Allianceの価格/販売は0.27です。
- Service Streamの価格/販売は0.27です。
- Saturn Oil & Gasの価格/販売は0.27です。
- eHealth Incの価格/販売は0.27です。
- Plastic Omnium SAの価格/販売は0.27です。
- Ford Motor Coの価格/販売は0.27です。
- Novabay Pharmaceuticals Incの価格/販売は0.27です。
- Munjal Auto Industriesの価格/販売は0.27です。
- JD Wetherspoon Plcの価格/販売は0.27です。
- Digital Wine Venturesの価格/販売は0.27です。
- Kawasaki Heavy Industriesの価格/販売は0.27です。
- UET United Electronic Technology AGの価格/販売は0.27です。
- China Glassの価格/販売は0.27です。